KLRK1 and lung carcinoma: Using A549 lung cancer and murine Lewis lung carcinoma models, applying either anti-PD-1 or anti-NKG2D antibodies in combination with oxaliplatin (OXA) synergistically suppresses tumor growth and prolongs mouse survival, offering a promising treatment benefit (100).